FDA Oncology Announcements

MEK inhibitor × Other × Clear all

6 Announcements

FDA approves selumetinib for adults with neurofibromatosis type 1 with symptomatic, inoperable plexiform neurofibromas

Trial: KOMET
Drug: KOSELUGO (selumetinib) · MEK inhibitor

FDA approves selumetinib for pediatric patients 1 year of age and older with neurofibromatosis type 1 with symptomatic, inoperable plexiform neurofibromas

Drug: KOSELUGO (selumetinib) · MEK inhibitor

FDA approves selumetinib for neurofibromatosis type 1 with symptomatic, inoperable plexiform neurofibromas

Drug: KOSELUGO (selumetinib) · MEK inhibitor

Trametinib/Dabrafenib

Drugs: Mekinist (trametinib) · MEK inhibitor, Tafinlar (dabrafenib) · BRAF inhibitor

Cobimetinib

Drug: COTELLIC Tablets (cobimetinib) · MEK inhibitor

FDA Approves Trametinib

Drug: MEKINIST tablet (trametinib) · MEK inhibitor